Xilio Therapeutics, Inc. (XLO)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $2.52 per share a year ago.
Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?
Xilio Therapeutics (XLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates
Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.22 per share a year ago.
Xilio Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ADD Andrew D. Dickinson GILEAD SCIENCES Inc. | 650,389 | $8.73M | $5.85M | -$2.88M | -32.94% |
| SRB Steve R. Bailey Frazier Life Sciences Management LP | 422,505 | $3.55M | $3.8M | $249,277.95 | 7.02% |
Xilio Therapeutics, Inc. (XLO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Xilio Therapeutics, Inc. ever had a stock split?
Xilio Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Rene Russo CEO | NASDAQ (NGS) Exchange | 98422T209 CUSIP |
| US Country | 76 Employees | - Last Dividend | 16 Mar 2026 Last Split | 22 Oct 2021 IPO Date |
Overview
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm focused on advancing immunotherapies for cancer treatment. These therapies are designed to bolster the immune system of cancer patients, offering new avenues for managing this complex disease. Established in 2016, Xilio is based in Waltham, Massachusetts, where it concentrates on the development of specialized drugs that have the potential to transform cancer treatment. With a robust pipeline of checkpoint inhibitors and cytokine therapies, Xilio aims to address the significant unmet needs in oncology by targeting the tumor microenvironment (TME) for more precise and effective interventions.
Products and Services
- XTX101 - A clinical-stage, tumor-selective anti-CTLA-4 monoclonal antibody (mAb) that is currently undergoing Phase 1/2 clinical trials for patients with solid tumors. XTX101 is designed to work by inhibiting CTLA-4, a checkpoint protein that can restrain the immune system from attacking cancer cells. Its tumor-selective approach means it aims to activate the immune system specifically within the tumor microenvironment, potentially reducing systemic side effects.
- XTX202 - A modified form of IL-2. This development project is part of Xilio's cytokine programs, where the traditional interleukin-2 (IL-2) molecule is re-engineered for enhanced efficacy and safety. IL-2 is a crucial cytokine in the immune system, known for its role in activating and expanding T cells, which can then attack cancer cells. However, its use has been limited due to severe side effects when administered in its conventional form. XTX202 is designed to overcome these limitations by being masked to regulate its activity until it is within the tumor microenvironment, potentially offering a more targeted and less toxic treatment option.
- XTX301 - An interleukin-12 (IL-12) product candidate. IL-12 is another potent cytokine that plays a significant role in the immune response to cancer. It can activate both innate (natural killer cells) and adaptive (T cells) immune responses against tumors. Similar to XTX202, XTX301 aims to provide a targeted way to exploit IL-12's therapeutic potential by reducing systemic exposure and focusing its activity within tumors, where it can stimulate the immune system without widespread toxicity.
- XTX401 - An interleukin-15 (IL-15) product candidate. IL-15 is involved in the development, maintenance, and activation of natural killer cells and memory T cells, both vital components of the immune response to cancer. By leveraging a similar masking strategy as its other cytokine programs, XTX401 is engineered to increase the safety and efficacy of IL-15 therapy. This approach ensures that the potent effects of IL-15 are localized to the tumor, minimizing side effects while potentially enhancing the immune system's ability to fight cancer.
